MedTrace Logo

Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer

NCT04966143 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-07-19

No results posted yet for this study

Summary

CLDN 18.2 chimeric antigen receptor T cells Clinical research plan for the treatment of recurrent or refractory pancreatic cancer.

Conditions

Interventions

BIOLOGICAL

LY011

Targeting CLDN 18.2 Car-T injection

Sponsors & Collaborators

  • Shanghai Longyao Biotechnology Inc., Ltd.

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2023-08-01
Completion
2024-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04966143 on ClinicalTrials.gov